A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511051-18-00

Acronym

ABI-4334-102

Enrollment

Registered

2024-07-30

Start date

Unknown

Completion date

2025-02-12

Last updated

2024-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B virus infection (cHBV)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026